UnitedHealth Stock Is Up More Than 30% in 1 Month and Pays a 2.5% Dividend Yield. Time to Buy?

UnitedHealth reported first-quarter adjusted EPS of $7.23 on revenue of $111.7 billion, while the medical care ratio improved to 83.9% from 84.8% a year earlier. Management raised full-year 2026 adjusted EPS guidance to more than $18.25 from more than $17.75, but membership declines and weaker Optum operating earnings temper the recovery story. The stock’s ~30% 30-day rebound and 2.5% dividend yield make it less compelling at roughly 19x guided earnings.

Analysis

UNH is transitioning from an idiosyncratic margin repair story into a more duration-sensitive “show-me” name. The near-term earnings reset is real, but the market has already moved to price in a cleaner claims trajectory and better pricing discipline; that reduces the asymmetry for new capital. In other words, the stock is no longer trading like a distressed turnaround, but it still carries turnaround-like execution risk.

The key second-order effect is competitive: if UNH is successfully repricing to offset higher utilization, peers with weaker scale or less diversified risk pools may have to follow, which can pressure broader managed-care margins over the next 2-4 quarters. The flip side is that membership attrition signals a potential elasticity limit—aggressive pricing can defend earnings but may gradually leak lives, especially in Medicare Advantage where benefit sensitivity and broker steering matter. That makes this less about a single quarter and more about whether UNH can stabilize retention while preserving rate adequacy into the next annual contracting cycle.

Optum is the swing factor the market may be underestimating. If services earnings remain soft while insurance margin improves, the “quality of earnings” narrative weakens and the multiple should compress, because investors are paying for a platform story, not just a P&C-like insurance recovery. The longer-horizon risk is that regulatory and reimbursement scrutiny intensifies precisely as the company starts to recover, capping how much of the earnings revision can translate into multiple expansion.

The contrarian view is that the stock may be neither cheap nor expensive—just less mispriced than a month ago. If consensus is extrapolating the improved medical care ratio linearly, the more prudent assumption is a mean reversion in both utilization and sentiment, which would make the current valuation look fair-to-full rather than compelling. That argues for trading the volatility around earnings and guidance updates instead of anchoring to the dividend yield as a margin of safety.

Key Decisions for Investors

• Avoid initiating fresh long exposure in UNH at current levels; if already long, trim 25-50% and reassess after the next quarterly print when retention and Optum trends can confirm whether margin repair is durable.
• For investors who want healthcare exposure, prefer a pair trade: long a lower-regulatory-risk diversified payer/benefits name versus short UNH on a 3-6 month horizon, aiming to capture potential multiple compression if Optum remains weak.
• Sell out-of-the-money UNH calls against existing stock for the next 1-2 quarters; the name has already repriced sharply, and covered calls monetize elevated implied volatility while capping downside from post-rally consolidation.
• If UNH pulls back 10-15% on any guide fatigue or membership-negative headline, consider a tactical long only on confirmation that medical care ratio improvement is holding; otherwise the risk/reward stays mediocre.
• Watch Medicare Advantage enrollment and Optum operating income as the real catalysts over the next 2 quarters; deterioration in either would likely negate the current recovery narrative faster than headline EPS revisions can support it.